Advantages and disadvantages of urate-lowering therapy in patients with asymptomatic hyperuricemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035731

Enrollment

Unknown

Registered

2020-08-16

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asymptomatic hyperuricemia

Interventions

Drug Intervention Group:Administer urate-lowering drugs

Non-drug Intervention Group:No intervention

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 75 years old, male or female; 2. Patients with hyperuricemia and no history of gout attacks and no joint uric acid stone formation was detected by ultrasound, and meeting one of the following criteria:a. Blood uric acid level > 8.0 mg/dl, with any of the following condition: Uric acid nephrolithiasis or renal function impairment (G2 stage and above), hypertension, abnormal glucose tolerance or diabetes, dyslipidemia, obesity, coronary heart disease, stroke, and cardiac function insufficiency; b. Blood uric acid level > 9.0 mg/dl; 3. Volunteer and sign informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with severe renal function impairment (eGFR < 30ml/min*1.73m2) (2009EP formula); 2. Patients with ALT or AST more than 2 times of the upper limit of normal (patients with abnormal liver function, but whose ALT or AST not exceed 3 times of the upper limit of normal, and can be explained by fatty liver can include into the study); 3. Women who are breast-feeding or pregnant, and those who plan to get pregnant, not willing to or havent take sufficient contraceptive measures during the period of childbearing age; 4. Have a history of allergy to any ingredient of uric acid lowering drugs; 5. Patients receiving azathiopurine or mercaptopurine therapy; 6. Inability or unwillingness to offer informed consent or to comply with the trial requirements; 7. Other factors researchers consider not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
Cardiovascular and cerebrovascular risk assessment in China;Major Adverse Cardiovascular Events;Liver fuction;serum lipid;	—

Secondary

Measure	Time frame
gout attack;Incidence of uric acid nephrolithiasis;eGFR;Blood pressure;	—

Countries

China

Contacts

Public ContactZou Hejian

Huashan Hospital, Fudan University

hjzou@unirheuma.org+86 13311881366

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026